Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Core Insights - Telomir Pharmaceuticals, Inc. has executed a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., which will secure worldwide rights to its lead investigational therapy, Telomir-1 [1] - The agreement aims to unify global IP rights and enable up to $5 million in potential shareholder contributions, strengthening Telomir's foundation for partnerships, licensing, and long-term value creation [1] Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies targeting epigenetic drivers of cancer, aging, and age-related diseases [1]